Company: LENZ
Filing Date: 2025-04-04
Form Type: 8-K
Source: 0001628280-25-016824
Chunk: 2

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit      Description                                                                                                
   Number                                                                                                                 
      1.1      Sales Agreement, dated April 4, 2025, between LENZ Therapeutics, Inc. and TD Securities (USA) LLC.         
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  LENZ THERAPEUTICS, INC.                                                                
  Dated: April 4, 2025                                                                   
                               By:         /s/ Daniel Chevallard                         
                               Name:       Daniel Chevallard                             
                               Title:      Chief Financial Officer                       
                                           (Principal Financial and Accounting Officer)